197 related articles for article (PubMed ID: 29575721)
1. Synthesis, Pharmacological Evaluation, and Docking Studies of Novel Pyridazinone-Based Cannabinoid Receptor Type 2 Ligands.
Ragusa G; Bencivenni S; Morales P; Callaway T; Hurst DP; Asproni B; Merighi S; Loriga G; Pinna GA; Reggio PH; Gessi S; Murineddu G
ChemMedChem; 2018 Jun; 13(11):1102-1114. PubMed ID: 29575721
[TBL] [Abstract][Full Text] [Related]
2. New pyridazinone-4-carboxamides as new cannabinoid receptor type-2 inverse agonists: Synthesis, pharmacological data and molecular docking.
Ragusa G; Gómez-Cañas M; Morales P; Rodríguez-Cueto C; Pazos MR; Asproni B; Cichero E; Fossa P; Pinna GA; Jagerovic N; Fernández-Ruiz J; Murineddu G
Eur J Med Chem; 2017 Feb; 127():398-412. PubMed ID: 28088085
[TBL] [Abstract][Full Text] [Related]
3. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro.
Thomas A; Baillie GL; Phillips AM; Razdan RK; Ross RA; Pertwee RG
Br J Pharmacol; 2007 Mar; 150(5):613-23. PubMed ID: 17245363
[TBL] [Abstract][Full Text] [Related]
4. The tamoxifen derivative ridaifen-B is a high affinity selective CB
Franks LN; Ford BM; Fujiwara T; Zhao H; Prather PL
Toxicol Appl Pharmacol; 2018 Aug; 353():31-42. PubMed ID: 29906493
[TBL] [Abstract][Full Text] [Related]
5. Developing pyridazine-3-carboxamides to be CB2 agonists: The design, synthesis, structure-activity relationships and docking studies.
Qian HY; Wang ZL; Xie XY; Pan YL; Li GJ; Xie X; Chen JZ
Eur J Med Chem; 2017 Sep; 137():598-611. PubMed ID: 28651225
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological data of cannabidiol- and cannabigerol-type phytocannabinoids acting on cannabinoid CB
Navarro G; Varani K; Lillo A; Vincenzi F; Rivas-Santisteban R; Raïch I; Reyes-Resina I; Ferreiro-Vera C; Borea PA; Sánchez de Medina V; Nadal X; Franco R
Pharmacol Res; 2020 Sep; 159():104940. PubMed ID: 32470563
[TBL] [Abstract][Full Text] [Related]
7. New Pyridone-Based Derivatives as Cannabinoid Receptor Type 2 Agonists.
Faúndez-Parraguez M; Alarcón-Miranda C; Cho YH; Pessoa-Mahana H; Gallardo-Garrido C; Chung H; Faúndez M; Pessoa-Mahana D
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681877
[TBL] [Abstract][Full Text] [Related]
8. CB2-selective cannabinoid receptor ligands: synthesis, pharmacological evaluation, and molecular modeling investigation of 1,8-Naphthyridin-2(1H)-one-3-carboxamides.
Lucchesi V; Hurst DP; Shore DM; Bertini S; Ehrmann BM; Allarà M; Lawrence L; Ligresti A; Minutolo F; Saccomanni G; Sharir H; Macchia M; Di Marzo V; Abood ME; Reggio PH; Manera C
J Med Chem; 2014 Nov; 57(21):8777-91. PubMed ID: 25272206
[TBL] [Abstract][Full Text] [Related]
9. Systematic Modification of the Substitution Pattern of the 7-Hydroxy-5-oxopyrazolo[4,3-
Mugnaini C; Kostrzewa M; Casini M; Kumar P; Catallo V; Allarà M; Guastaferro L; Brizzi A; Paolino M; Tafi A; Kapatais C; Giorgi G; Vacondio F; Mor M; Corelli F; Ligresti A
Molecules; 2023 Jun; 28(13):. PubMed ID: 37446625
[TBL] [Abstract][Full Text] [Related]
10. Tricyclic pyrazoles. Part 8. Synthesis, biological evaluation and modelling of tricyclic pyrazole carboxamides as potential CB2 receptor ligands with antagonist/inverse agonist properties.
Deiana V; Gómez-Cañas M; Pazos MR; Fernández-Ruiz J; Asproni B; Cichero E; Fossa P; Muñoz E; Deligia F; Murineddu G; García-Arencibia M; Pinna GA
Eur J Med Chem; 2016 Apr; 112():66-80. PubMed ID: 26890113
[TBL] [Abstract][Full Text] [Related]
11. 7-Azaindolequinuclidinones (7-AIQD): A novel class of cannabinoid 1 (CB1) and cannabinoid 2 (CB2) receptor ligands.
Penthala NR; Shoeib A; Dachavaram SS; Cabanlong CV; Yang J; Zhan CG; Prather PL; Crooks PA
Bioorg Med Chem Lett; 2020 Nov; 30(22):127501. PubMed ID: 32882418
[TBL] [Abstract][Full Text] [Related]
12. Design, Synthesis, and SAR Studies of Heteroarylpyrimidines and Heteroaryltriazines as CB
Qian HY; Wang ZL; Chen LL; Pan YL; Xie XY; Xie X; Chen JZ
ChemMedChem; 2018 Nov; 13(22):2455-2463. PubMed ID: 30246417
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo pharmacological characterization of two novel selective cannabinoid CB(2) receptor inverse agonists.
Cascio MG; Bolognini D; Pertwee RG; Palazzo E; Corelli F; Pasquini S; Di Marzo V; Maione S
Pharmacol Res; 2010 Apr; 61(4):349-54. PubMed ID: 19961936
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor.
Iwamura H; Suzuki H; Ueda Y; Kaya T; Inaba T
J Pharmacol Exp Ther; 2001 Feb; 296(2):420-5. PubMed ID: 11160626
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and pharmacological evaluation of new biphenylic derivatives as CB2 receptor ligands.
Bertini S; Chicca A; Arena C; Chicca S; Saccomanni G; Gertsch J; Manera C; Macchia M
Eur J Med Chem; 2016 Jun; 116():252-266. PubMed ID: 27078864
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and structure activity relationship investigation of triazolo[1,5-a]pyrimidines as CB2 cannabinoid receptor inverse agonists.
Aghazadeh Tabrizi M; Baraldi PG; Ruggiero E; Saponaro G; Baraldi S; Poli G; Tuccinardi T; Ravani A; Vincenzi F; Borea PA; Varani K
Eur J Med Chem; 2016 May; 113():11-27. PubMed ID: 26922225
[TBL] [Abstract][Full Text] [Related]
17. Crystal Structure of the Human Cannabinoid Receptor CB2.
Li X; Hua T; Vemuri K; Ho JH; Wu Y; Wu L; Popov P; Benchama O; Zvonok N; Locke K; Qu L; Han GW; Iyer MR; Cinar R; Coffey NJ; Wang J; Wu M; Katritch V; Zhao S; Kunos G; Bohn LM; Makriyannis A; Stevens RC; Liu ZJ
Cell; 2019 Jan; 176(3):459-467.e13. PubMed ID: 30639103
[TBL] [Abstract][Full Text] [Related]
18. Novel pyrrolocycloalkylpyrazole analogues as CB
Asproni B; Manca I; Pinna G; Cichero E; Fossa P; Murineddu G; Lazzari P; Loriga G; Pinna GA
Chem Biol Drug Des; 2018 Jan; 91(1):181-193. PubMed ID: 28675787
[TBL] [Abstract][Full Text] [Related]
19. Involvement of the CB
Khan MI; Sobocińska AA; Brodaczewska KK; Zielniok K; Gajewska M; Kieda C; Czarnecka AM; Szczylik C
BMC Cancer; 2018 May; 18(1):583. PubMed ID: 29792186
[TBL] [Abstract][Full Text] [Related]
20. Pharmacomodulations around the 4-oxo-1,4-dihydroquinoline-3-carboxamides, a class of potent CB2-selective cannabinoid receptor ligands: consequences in receptor affinity and functionality.
Stern E; Muccioli GG; Bosier B; Hamtiaux L; Millet R; Poupaert JH; Hénichart JP; Depreux P; Goossens JF; Lambert DM
J Med Chem; 2007 Nov; 50(22):5471-84. PubMed ID: 17915849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]